Inquiry

Vertebrate Model-based In Vivo Screening Service

Leading the Way in Innovative In Vivo Screening Solutions with Vertebrate Models

Vertebrate animal models provide a theoretical foundation for the development of cognitive therapeutics for many glycobiology diseases, and tissue engineering, and have a wide range of applications in the field of disease modeling and chemical screening. As a professional glycobiology company, CD BioGlyco has the world's leading biology and chemistry skills and extensive experience in the field of Glycobiology Disease Model Development, providing reliable vertebrate model-based in vivo screening services to clients.

Initial construction of a vertebrate model
We construct different types of vertebrate models by biochemical or chemical induction and gene knockout and use them to screen for glycobiomarkers and glycogenes. We offer a variety of ways to custom-construct vertebrate models for our clients.
- Chemical induction: we mimic the onset and development of human glycobiology diseases by injecting specific chemicals into experimental vertebrates to trigger physiological responses.
- Gene editing: we perform conditional target gene research in vertebrates by precise glycan gene editing to specific vertebrates through the Cre-loxP site-specific recombination system.
- Alien transplantation: we mimic human glycobiology diseases by transplanting human hematopoietic stem cells, immune cells, or tissues into immunodeficient vertebrates, and then screen libraries of small molecules for glycobiomarkers and glycogenes that inhibit the disease phenotype.
Glycobiomarkers and glycogenes screening and evaluation
We perform specific treatments, such as glycoprotein extraction and glycan chain release, by selecting appropriate vertebrate models.
Then, we screen and research glycogenes by biotechnological means, such as metabolomics and RNA interference. Specific services encompass technologies such as gene sequencing, gene expression analysis, and functional genomics.
Next, we perform qualitative and quantitative analysis of glycobiomarkers and glycogenes in vertebrate models using appropriate assay technologies such as mass spectrometry, glycosylation analysis, gene sequencing, and so on.
Finally, we provide a comprehensive analysis of the assay results (gene function analysis, pathway analysis, bioinformatics analysis) to identify significantly different glycobiomarkers and glycogenes. The screened glycobiomarkers and glycogenes are then validated to confirm their use in disease diagnosis, prevention, or treatment.

Processes of in vivo screening for glyco-genes and glyco-biomarkers in vertebrate models. (CD BioGlyco)

Here, depending on the animal species, we offer many types of In Vivo Glycobiology Disease Model Screening Services to our clients:

Mice Model-based In Vivo Screening Service

We develop mouse models using gene editing technology and apply them in the field of glycobiology disease research. We provide our clients with C-NKG, NOD-Scid, Tcra KO, and many other types of immunodeficiency mouse models.

Rat Model-based In Vivo Screening Service

We provide our clients with genome-wide rats that are richer in intervention targets by making in situ substitutions of rat-derived genes.

Zebrafish Model-based In Vivo Screening Service

Zebrafish have a diverse glycan structure. We rapidly establish stable transgenic or mutant zebrafish glycobiology disease models through chemotherapy, gene knockout, gene overexpression, and xenografts. We utilize high-throughput screening tools to screen for potential genes or biomarkers of disease development, both biologically and chemically.

Frog Model-based In Vivo Screening Service

The frog genome shows higher similarity to mammalian genomes. We utilize CRISPR/Cas9 technology that screens for candidate glycobiology disease genes in frogs.

Pig Model-based In Vivo Screening Service

Pigs are genetically diverse, which facilitates selection based on specific needs. Therefore, we utilize pig disease models to be able to screen for glycobiomarkers and glycogenes on a larger scale.

Marmoset Model-based In Vivo Screening Service

Marmoset is an excellent model for researching the visual system, auditory system, cognitive functions, and connectivity. We manipulate it using gene editing technologies to screen for glycogenes that are linked to visual, auditory, and cognitive functions.

Rhesus Monkey Model-based In Vivo Screening Service

The high similarity of brain anatomy and physiological functions of the rhesus monkey to those of humans makes it an ideal animal model to mimic human glycobiology diseases. We develop models by genetic manipulation or drug induction and screen for glycobiomarkers or glycogenes.

Rabbit Model-based In Vivo Screening Service

In the rabbit model, we use metabolomics, RNA interference, and other techniques to damage rabbit pancreas or islet cells to explore the metabolic process of polysaccharides and screen for glycobiomarkers and glycogenes.

Humanized Mice Model-based In Vivo Screening Service

We use transgenic or homologous recombination methods to "place" human genes in a mice model to prepare the humanized mice model, which can be used to effectively detect IgG and IgM antibodies, explore the mechanism of the human immune system, and also be used to detect tumor growth and metastasis.

Dog Model-based In Vivo Screening Service

We utilize biological techniques to provide our clients with dog models of various glycobiological diseases such as GCK gene mutation, or insulin deficiency, which helps our clients to conduct basic research on glycobiology diseases and glycan screening.

Sheep Model-based In Vivo Screening Service

We disrupt insulin resistance and pancreatic β-cell secretion in sheep through gene editing techniques, leading to insulin deficiency, and then use techniques such as metabolomics to mimic signaling processes in a low-sugar environment.

Publication Data

Technology: Zebrafish model

Journal: Genes

IF: 3.5

Published: 2020

Results: In this research, the authors developed a sophisticated drug screening system for Alexander disease (AxD) using the zebrafish model. Also, the authors evaluated embryos expressing the human glial progenitor fibrillary acidic protein (GFAP) gene carrying p.R239C under the control of the zebrafish gfap gene promoter for the analysis of localized mutant GFAP inclusions, ultrastructural analysis of cells expressing the mutant GFAP, the efficacy of ceftriaxone treatment, and the heat shock response. All experimental results indicate that zebrafish is a suitable model for researching the molecular pathogenesis of GFAP mutations and for pharmacological screening.

Fig.1 Diagram of immunofluorescence analysis of zebrafish model cells. Fig.1 Immunofluorescence analysis of transverse sections. (Candiani, et al., 2020)

Applications

Vertebrate models have a high physiological and genetic similarity to humans; thus, model-based in vivo screening can be used to more accurately model the onset and progression of human glycolytic diseases.
Vertebrate models can be used to model a variety of diseases, including diabetes, obesity, metabolic syndrome, and other disease models.
Due to the small size, high egg production, rapid development, and embryonic transparency of vertebrate models, they can be used to conduct in vivo drug screening on a large scale.

Advantages

We have a specialized glycobiology disease model development platform to provide custom animal model construction and screening services.
We provide knock-in or knock-out specific genes in vertebrate models through biological techniques to establish specific disease models, thus accelerating the progress of our clients' drug research.
All of our experimental protocols undergo rigorous quality testing to ensure that we provide our clients with high-quality animal models of glycobiology disease.

CD BioGlyco's in vivo screening services based on vertebrate models provide powerful tools for disease research and drug development. These models help researchers better understand the mechanisms of disease onset and progression and accelerate the pace of new drug development. Please feel free to contact us if you are interested in our vertebrate model-based in vivo screening service.

Reference